Morningstar

Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors

Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
Healio

RAAS inhibitors show pediatric CKD benefit vs. calcium channel blockers

Renin-angiotensin-aldosterone system inhibitors were linked to better pediatric chronic kidney disease outcomes compared with ...
ascopubs.org

Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a ...

Adjuvant transarterial chemoembolization with sorafenib for patients with hepatocellular carcinoma with portal vein tumor thrombus after surgery: A phase III, multicenter, randomized, controlled trial ...
ascopubs.org

ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid ...

Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell ...
WebMD

Farxiga and Heart Failure: What You Need to Know

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally, sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...
WebMD

Preventing Heart Failure Complications With Entresto

Some people with heart failure need to take multiple medicines each day in order to keep their symptoms under control. Heart failure not only leads to issues in the heart but other organs in the body ...